Previous 10 |
Top-line data at month 12 in a Phase 1/2a clinical trial, SCiStar , evaluating Asterias Biotherapeutics' (NYSEMKT: AST ) OPC1 cells in patients with severe spinal cord injuries showed a sustained effect. More news on: Asterias Biotherapeutics, Inc., Healthcare stocks news, Stocks on the m...
FREMONT, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today ...
News, Short Squeeze, Breakout and More Instantly...
Asterias Biotherapeutics Inc. Common Series A Company Name:
AST Stock Symbol:
NYSE Market:
(TheNewswire) VANCOUVER, BC – TheNewswire - February 29, 2024 – Astron Connect Inc. (the “Company” or “Astron”) (TSXV:AST) today announced its first quarter results for the thre...
(TheNewswire) VANCOUVER, BC – TheNewswire -- January 26, 2024 – Astron Connect Inc. (TSXV:AST) (the “Company” or “Astron”) (TSX-V:AST) today announced its full year results for the fi...
(TheNewswire) VANCOUVER, British Columbia – TheNewswire - December 8 , 2023 -- Astron Connect Inc. (TSXV:AST) (“Astron” or the “Company”) announces that the Company has changed its auditor fro...